WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Dec. 13, 2005--Merck & Co., Inc. today announced changes to the product label for SINGULAIR(R) (montelukast sodium), which includes new information from a 56-week clinical study that demonstrated that children with asthma (6-8 years of age) taking SINGULAIR 5 mg tablets once daily had similar growth rates as children taking placebo. In the same study, children taking the inhaled steroid beclomethasone dipropionate 168 mcg twice daily had slower growth rates than children on either SINGULAIR or placebo.
